NCT07290244: Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
- State
- Under way
- Phase
- Phase 1
- People
- 18 planned
- Started
- 2 Mar 2026
- Primary completion
- May 2027
- Arms
- OAG - Low Dose ER-100 (2 x 10^11 vg/eye), OAG - High Dose ER-100 (6 x 10^11 vg/eye), NAION - Selected Dose ER-100
- Results
- None posted
- 18 Dec 2025: Trial registered
- 2 Mar 2026: Trial started